3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
23
Ovarian Neoplasms
18
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
9
Prostatic Neoplasms
9
Pancreatic Neoplasms
8
Neoplasms
8
Fallopian Tube Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
4
Advanced Solid Tumors
4
Small Cell Lung Carcinoma
3
Recurrence
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Squamous Cell
3
Solid Tumors
2
Sarcoma
2
Neuroendocrine Tumors
2
Lymphoma
2
Lung Neoplasms
2
Hodgkin Disease
2
Fanconi Anemia, Complementation Group D1
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumours
2
Advanced Solid Tumor
2
Advanced Cancer
2
Triple Negative Metastatic Breast Cancer
1
Thymoma
1
Thrombocytosis
1
Solid Tumor
1
Interventions
Cyclophosphamide
3
pembrolizumab
2
Radiotherapy
2
Radiation
2
Gemcitabine
2
Etoposide
2
Doxorubicin
2
Cryotherapy
2
Cryosurgery
2
tocilizumab
1
selinexor
1
robatumumab
1
poly ICLC
1
olaparib
1
montanide ISA 51
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
flt3 ligand protein
1
eltrombopag
1
cc-486
1
Vincristine
1
Trabectedin
1
Temozolomide
1
Radiotherapy, Intensity-Modulated
1
Leukapheresis
1
Irinotecan
1
Interleukin-2
1
Injections
1
Imiquimod
1
Ifosfamide
1
Denosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Bone Neoplasms
×
olaparib
×
Clear all
NCT02398058
2021-04-14
TOMAS
Italian Sarcoma Group
Phase 1
Completed
50 enrolled